-
CanSino Biotechnology Partners with AstraZeneca for mRNA Vaccine Development and Manufacturing
•
China-based vaccines specialist CanSino Biologics Inc., (HKG: 6185) has announced a product supply cooperation framework agreement with UK pharmaceutical major AstraZeneca (AZ, NASDAQ: AZN). The agreement entails providing contract development and manufacturing services for AstraZeneca’s mRNA vaccine, with no financial details disclosed. Focus on mRNA Production Platform and Vaccine R&DThis…
-
Lynk Pharmaceuticals’ LNK01001 Shows Positive Results in Atopic Dermatitis Phase II Study
•
China-based Lynk Pharmaceuticals Co., Ltd has announced that its Phase II clinical study for LNK01001 in atopic dermatitis (AD) has yielded positive major results. The study, a randomized, double-blinded, placebo-controlled, multi-center trial, enrolled 150 patients and included high-dose and low-dose groups of LNK01001 alongside a placebo group. Study Design and…
-
BioNTech Expands Partnership with Duality Biologics for Global Rights to ADC DB-1305
•
Germany-based BioNTech SE (NASDAQ: BNTC) has entered into a cooperation expansion agreement with its existing partner, Duality Biologics (Suzhou) Co., Ltd. This new deal grants BioNTech global development, manufacturing, and commercialization rights to the antibody drug conjugate (ADC) DB-1305, excluding Greater China, which includes China mainland, Hong Kong, and Macau.…
-
Johnson & Johnson Reaches Settlement with Fresenius Kabi and Formycon AG for Stelara Biosimilar
•
US pharmaceutical giant Johnson & Johnson (J&J; NYSE: JNJ) has entered into its latest settlement agreement with Fresenius Kabi and Formycon AG, granting the companies a license to launch their biosimilar version of ustekinumab, FYB202, no later than April 15, 2025. This marks the third agreement signed by J&J with…
-
VistaGen’s Fasedienol Phase III Success Sends Shares Soaring Over 600%
•
Shares of San Francisco-based biotech VistaGen (NASDAQ: VTGN) experienced a dramatic increase of over 600% by the end of trading yesterday, following the release of positive topline Phase III data for fasedienol, a novel rapid-onset nasal spray treatment for social anxiety disorder (SAD). The PALISADE-2 study demonstrated that fasedienol achieved…
-
Nektar Therapeutics and Eli Lilly & Co. Face Off in Court Over REZPEG Partnership Dispute
•
A legal feud between US-based Nektar Therapeutics (NASDAQ: NKTR) and pharmaceutical giant Eli Lilly & Co. (NYSE: LLY) is unfolding over alleged conflicts of interest and botched data analysis related to their partnership for the development of rezpegaldesleukin (REZPEG; NKTR-358), a first-in-class regulatory T (Treg) cell stimulator targeting the interleukin-2…
-
BioCity Biopharma Receives FDA IND Approval for CD3-EGFR BsAb BC3448
•
China-based biotechnology company BioCity Biopharma has announced that it has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for its cluster of differentiation-3 (CD3) epidermal growth factor receptor (EGFR)-targeted bispecific antibody (BsAb), BC3448. With this approval, the company will now initiate a Phase I…
-
Zai Lab Ltd Reports Q2 2023 Financials with 53% YOY Product Revenue Growth
•
China-based Zai Lab Ltd (NASDAQ: ZLAB; HKG: 9688) has released its financial results for the second quarter of 2023, along with recent product highlights and corporate updates. The company reported total product revenues of USD 68.9 million for the quarter, marking a 53% year-on-year (YOY) increase at constant exchange rates.…
